Needle-Free Drug Delivery Devices Market

The market for needle-free drug delivery devices is anticipated to grow from US$ 16.01 billion in 2024 to US$ 28.42 billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.5% during the period from 2025 to 2031. Key trends driving the needle-free drug delivery devices market include an increase in strategic initiatives and the adoption of healthcare integration software.

Analysis of the Needle-Free Drug Delivery Devices Market

Needles pose risks of various diseases, including HIV, and can cause injuries if not handled with care. According to the article "MEDICSEN: NEEDLE-FREE SMARTPATCH FOR PAINLESS DRUG DELIVERY", more than 2,000 individuals in the US experience needlestick injuries daily, resulting in over US$ 3 billion in related costs each year. The adoption of needle-free drug delivery devices significantly reduces the risk of such injuries and diseases. Consequently, the rising incidence of needlestick injuries and increased spending on treatment are propelling the growth of the needle-free drug delivery devices market.

Overview of the Needle-Free Drug Delivery Devices Market

Needle-free drug delivery methods include power sprays, jet injectors, inhalers, and skin patches. This technology alleviates patient anxiety associated with needles. Needle-free devices provide effective injections for a variety of medications and are bioequivalent to traditional needles. The benefits of needle-free delivery systems, such as reduced pain, rapid administration, elimination of needle disposal issues, and the ability for self-administration, are primarily driving the rising demand for these devices.

Strategic Insights

Drivers and Opportunities in the Needle-Free Drug Delivery Devices Market

Increasing Incidence of Chronic Diseases and Lifestyle Disorders to Benefit the Market

Chronic conditions like heart disease, diabetes, and cancer are among the leading causes of mortality and disability globally. According to the Centers for Disease Control and Prevention (CDC), approximately 38.4 million Americans were diagnosed with diabetes in 2021. To manage diabetes, insulin is regularly injected into the subcutaneous layer. The growing prevalence of diabetes is driving the demand for insulin injections. Companies are increasingly focusing on developing needle-free insulin delivery systems to prevent needlestick injuries. For example, Medicsen is working on the SmartPatch to enhance insulin delivery efficiency.

Growing Preference for Home Healthcare - A Chance for the Needle-Free Drug Delivery Market

The transition from hospitals and long-term care facilities to home care settings enhances the potential for improved, consistent, and timely interactions between patients and healthcare providers, facilitated by the increasing use of cloud-based and mobile medical devices. In developing nations, the number of patients receiving home therapy has historically been limited. Smart patches and jet injectors that integrate with electronic health records (EHR) enable doctors to monitor dosages remotely. With needle-free drug delivery devices, patients can conveniently self-administer their medications as prescribed by their healthcare providers. Therefore, the rising emphasis on home healthcare and the adoption of technologically advanced products are expected to create growth opportunities for the market during the forecast period.

Segmentation Analysis of the Needle-Free Drug Delivery Devices Market Report

Key segments contributing to the analysis of the needle-free drug delivery devices market include type and application.

By type, the needle-free drug delivery devices market is categorized into inhalers, jet injectors, novel needles, transdermal patches, and others. The jet injectors segment accounted for the largest market share in 2023.By application, the market is divided into insulin delivery, vaccination, pain management, and others. The insulin delivery segment led the market in 2023.

Geographical Analysis of the Needle-Free Drug Delivery Devices Market Share

The geographical scope of the needle-free drug delivery devices market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America.

North America was the leading region in the needle-free drug delivery devices market in 2023. The growth in this region is driven by the rising demand for medications for rare diseases from biopharmaceutical and biotechnology firms, the presence of major market players, an increase in product launches, a growing incidence of needlestick injuries, and extensive research and development efforts by academic institutions and pharmaceutical companies. Additionally, the Asia Pacific region is expected to exhibit the highest CAGR in the coming years.

Recent Developments and News in the Needle-Free Drug Delivery Devices Market

The evaluation of the needle-free drug delivery devices market is based on qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the needle-free drug delivery devices market:

NovaXS, established at the University of California, Berkeley, has developed its patent-pending Telosis technology, which administers a narrow stream of medication without a needle in just 0.3 seconds and analyzes injection data to facilitate smarter health decisions. (Source: NovaXS BIotech, Press Release, 2022)NuGen Medical Devices Inc. introduced InsuJet devices in Canada. SOL-MILLENNIUM Medical Group participated as an exhibitor at the 2022 Diabetes Canada/Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference, where it launched the InsuJet product for the Canadian market. (Source: NuGen Medical Devices Inc, Company Website, 2022